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Summary
With rising life expectancy, the importance of patient-related prognostic
factors and how to integrate such data into clinical decision-making
becomes increasingly important. The aim of this study was to evaluate the
prognostic impact of smoking status in patients with acute myeloid leukae-
mia (AML) treated with intensive chemotherapy. We conducted a nation-
wide cohort study based on data obtained from the Danish National
Leukaemia Registry (DNLR). The study comprised Danish patients aged
18–75 years, diagnosed with AML between 1 January 2000 and 31 Decem-
ber 2012. Medical records were reviewed and data on smoking status were
collected. A total of 1040 patients (median age 59 years) were included,
and 602 patients (589%) were categorised as ever-smokers and the remain-
ing as never-smokers. Kaplan–Meier survival estimates revealed that ever-
smokers had a significant shorter median overall survival (OS) at
172 months [95% CI (149;191)] compared to never-smokers at
245 months (95% CI [192;307]). Multivariate analysis revealed smoking
status as a significant prognostic factor for inferior OS with a hazard ratio
(HR) of 122 [95% CI (104;144)]. In conclusion, smoking status was
found to be associated with inferior OS in intensively treated AML
patients.
Keywords: acute myeloid leukaemia, AML, prognosis, tobacco-smoking,
lifestyle factors, population.
Introduction
Acute myeloid leukaemia (AML) is an aggressive haemato-
logical malignancy arising from clonal expansion of pluripo-
tent haematopoietic stem cells or common progenitor cells,
resulting in bone marrow failure and subsequent risk of life-
threatening bleeding and infections. Factors affecting the
prognosis of AML have been intensively studied over the past
decades and can be subdivided into those which are patient-
related (e.g. age, performance status and comorbidity) or dis-
ease-related (e.g. molecular genetics and cytogenetic alter-
ations, laboratory findings at diagnosis, prior haematological
disease or cytotoxic treatment for cancer).1,2 The patient-re-
lated factors predict risk of therapy-related death, and the
disease- or leukaemia-related factors predict response to
chemotherapy and remission durability.1,2
The risk of AML among smokers has been an area of
interest, with evidence suggesting that previous or an active
tobacco-smoking history is associated with up to 40% higher
incidence of AML.3 Tobacco smoking has also been corre-
lated to worse outcomes following haematopoietic stem cell
transplantation (HSCT).4,5 Tobacco-smoking is carcinogenic
with a causal role in the development of several types of can-
cer, as well as being one of the strongest risk factors for car-
diovascular and pulmonary diseases. The latter two can have
detrimental effects on chemotherapy tolerance and poorer
outcomes among smokers have been observed in several can-
cers,6 including ovarian cancer,7 head and neck cancer,8,9
lung cancer,10 renal cell carcinoma,11 colorectal cancer12 and
non-Hodgkin lymphoma.13
The influence of lifestyle and socioeconomic factors on
the prognosis in AML are either poorly studied or show a
minimal effect with a few exceptions.14,15 With ageing popu-
lations in the Western world and a growing armamentarium
of active therapies against AML, it is imperative that we
understand the impact of comorbidities and lifestyle factors
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on treatment outcomes. For example, a higher risk of early
treatment-related mortality (TRM) may lead physicians to
refrain from intensive therapies and consider those which are
novel and less intensive. However, knowledge on how to
integrate factors like lifestyle and comorbidity in clinical
decision-making remains limited.
The aim of this study was to evaluate the prognostic
impact of smoking status on overall survival (OS) of patients
with AML treated with intensive chemotherapy regimens in
Denmark between 2000 and 2012.
Materials and methods
Patients
The Danish population (58 million people) has free access
to medical care provided by the tax-supported public health-
care system. Intensive treatment of AML is fully centralised
to tertiary haematology clinics at university hospitals. Danish
residents are assigned a unique civil registration number
(CPR-number) at birth or immigration. The CPR registry
covers information on name and residential address in addi-
tion to vital status for the entire Danish population. The
Danish National Leukaemia Registry (DNLR)16 was estab-
lished in 2000 by the Danish Acute Leukaemia Group (ALG)
and includes detailed data on all adult acute leukaemia
patients treated in Denmark. DNLR is described in detail
elsewhere.16 A validation study from 2013 found that cover-
age was comprehensive, with 99% of AML patients diag-
nosed in Denmark included in the DNLR.17
In this nationwide Danish cohort study, the DNLR was
surveyed for patients diagnosed with AML at age 18–75 years
in the time period of 1 January 2000 to 31 December 2012
and who had been treated with intensive chemotherapy.
Intensive chemotherapy was defined as treatments aimed at
inducing complete remission (CR). More precisely, the treat-
ments had to include a minimum of one course of
chemotherapy, containing a standard to high dose of cytara-
bine (≥ 200 mg/m2/day) for at least five days, in combina-
tion with an anthracycline (daunorubicin or idarubicin) or
anthracycline-related compound (mitoxantrone). Patients
with acute promyelocytic leukaemia were excluded.
Exposure and outcome
Medical records from the time of diagnosis for the AML
patients fulfilling the inclusion criteria were retrieved, and
information on lifestyle factors, including comorbidities,
alcohol consumption and smoking habits were collected.
Information regarding smoking habits were given as never,
former and current, based on the clinical notes from the
time of diagnosis. Information on comorbidities, including
diabetes mellitus, chronic obstructive pulmonary disease,
ischaemic heart disease, rheumatological disease, hyperten-
sion and hypercholesterolaemia were also collected directly
from clinical notes. Data on exposure were merged with the
prospectively collected baseline clinicopathological features,
as well as the treatment details and outcome data from the
DNLR, using the CPR-number as link.
Statistical analysis
Patients were followed from the date of AML diagnosis until
either death, emigration or end of follow-up (24 April 2015).
Smoking status was dichotomised into never- and ever-
smoking, with the latter including both former and current
smokers. Descriptive statistics were summarised and categori-
cal variables were presented as percentage, and continuous
variables as median and range for non-normally distributed,
and mean and range for normally distributed. Variables were
compared to explore univariate associations between smok-
ing status as the dependent variable and the variable of inter-
est. To assess differences, the chi-squared test was used for
categorical variables and the Wilcoxon rank-sum test for
continuous variables.
Crude survival curves were calculated using the Kaplan–
Meier method and the log-rank (Mantel–Cox) test was used
for statistical testing of differences in OS. The independent
association between covariates and OS was examined in mul-
tivariate Cox proportional hazard regression analysis, includ-
ing age, gender, BMI, comorbidities, WHO performance
status, AML presentation and smoking status. All statistical
analyses were made using R version 36.0 (R Core Team,
2019), and a P-value < 005 was considered as statistically
significant. The study was approved by the Danish Data Pro-
tection Agency (jr. nr. 2008-58-0028).
Results
Patient characteristics
A total of 1489 patients aged 18–75 years were diagnosed
with AML and received intensive chemotherapy between 1
January 2000 and 31 December 2012. However, medical
records only included information on smoking status for
1040 of the patients (698%). Table I summarises the baseline
characteristics of the patients; median age was 59 years and
male to female ratio was 125. The median follow-up time
was 35 years. Of the 1040 patients, 804% had de novo
AML, whereas 161% and 36% had secondary AML (sAML)
and therapy-related AML (tAML), respectively. A total of
602 patients were ever-smokers (579%), of whom 362%
were categorised as current smokers and 217% as former
smokers. The remaining 438 patients (421%) had no history
of smoking and formed the never-smoker group. Of the
never-smoker group, 479% were female patients and 521%
were male patients, whereas of the ever-smoker group, 390%
were female patients and 610% were male patients. Never-
smokers were more likely to present as sAML, compared to
ever-smokers (192% and 138% respectively; P = 002).
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When investigating comorbidity and WHO performance sta-
tus, the ever-smoker group tended to have a higher WHO-
performance status (P = 0069). In addition, ever-smokers
had significantly more comorbidities compared to never-
smokers (P = 0006), including 131% having ≥ 2 comorbidi-
ties, compared to 75% in the never-smoker group.
Overall survival and smoking status
Table II shows the OS for all AML patients included in the
study, as well as OS by smoking status. The median OS was
187 months [95% CI (172;213)] for the whole cohort.
Female patients had a significantly longer median OS of
225 months [95% CI (178;289)] as compared to male
patients [175 months 95% CI (153;197), P = 0002].
When stratifying for smoking status, ever-smokers had a
significantly shorter median OS of 172 months [95% CI
(149;191)] compared to never-smokers, who had a median
of 245 months [95% CI (192;307), P = 0001] (Fig 1).
When stratifying for gender and smoking status, female
never-smokers had a longer median OS compared to male
never-smokers (P = 0013); however, for ever-smokers no
differences in median OS was observed between females and
males (P = 0200). While no difference in median OS was
found between male patients according to smoking status
(P = 0178), female ever-smokers had a significantly shorter
median OS of 174 months [95% CI (142,251)] as com-
pared to the 284 months for female never-smokers [95% CI
(208;584), P = 0008] (Fig 2). Patients aged ≥ 60 years
remained associated with inferior survival in both ever-smo-
ker and never-smoker groups. When comparing OS by age
(≥ 60 or < 60 years) in the never- and ever-smokers, OS was
significantly lower in the ever-smokers compared to the
never-smokers (P = 0035 and 0027, respectively) (Fig 2).
Multivariate analysis
Multivariate analysis adjusting for age, gender, BMI, comor-
bidities, WHO performance status (WHO-PS), AML presen-
tation and smoking status as covariates are shown in
Table III. Ever-smoker status was associated with a hazard
ratio (HR) of 122 [95% CI (104;144)] for an event (death)
compared to that of never-smokers (P = 001). Being aged ≥
60 years was associated with a HR of 184 [95% CI
(156;2016), P < 0001]. Performance status was associated
with inferior survival with a HR of 124 [95% CI (104;148),
P = 0016] for WHO-PS = 1 and HR 176 [95% CI
(141;220), P < 0001] for WHO-PS ≥ 2. Additionally,
Table I. Comparison of selected baseline characteristics of the study cohort and stratification by smoking status.
Characteristics Total (n = 1040) Never-smokers (n = 438) Ever-smokers (n = 602) P-value
Gender <0001
Male, n (%) 577 (555) 210 (479) 367 (610)
Female, n (%) 463 (445) 228 (521) 235 (390)
Age, median, years (range) 59 (18-75) 58 (18-75) 59 (18-75)
≥ 60 y, n (%) 484 (465) 197 (450) 287 (477) 0425
Comorbidity, n (%) 0006
0 680 (654) 306 (699) 374 (621)
1 207 (199) 82 (187) 125 (208)
≥2 112 (108) 33 (75) 79 (131)
ND 41 (39) 17 (39) 24 (40)
WHO PS, n (%) 0069
0 348 (333) 160 (365) 188 (312)
1 501 (482) 211 (482) 290 (482)
≥ 2 188 (181) 67 (153) 121 (201)
BMI, mean (range) 2599 (156 - 606) 2621 (156 - 515) 2583 (168 - 606) 0215
Response to first treatment 0990
CR achieved, n (%) 625 (601) 265 (605) 360 (598)
CR not achieved, n (%) 228 (219) 96 (219) 132 (219)
CR ND, n (%) 187 (180) 77 (176) 100 (183)
HSCT, n (%) 114 (110) 56 (128) 58 (96) 0132
BMB, median, % (range) 56 (0-100) 53 (0-100) 60 (0-100) 0065
AML presentation, n (%) 0015
dn-AML 836 (804) 344 (785) 492 (817)
sAML 167 (161) 84 (192) 83 (138)
tAML 37 (36) 10 (23) 27 (45)
HSCT, haematopoietic stem cell transplantation; BMB, bone marrow blasts; CR, complete remission; AML, acute myeloid leukaemia; dn-AML, de
novo AML; sAML, secondary AML; tAML, therapy-related AML; BMI, Body Mass Index; WHO-PS, World Health Organisation performance
score; P-value, probability value comparing ever-smokers and never-smokers.
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Fig 1. Crude survival and 95% CI for 1080 patients with acute myeloid leukaemia (AML) by smoking status for all patients. Survival time is dis-
played as time after diagnosis. P-value from log-rank test. [Colour figure can be viewed at wileyonlinelibrary.com]
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Fig 2. Crude survival and 95% CI for 1080 patients with acute myeloid leukaemia (AML) by smoking status for (upper left) male, (bottom left)
female, (upper right) with age <60 years and (bottom right) with age ≥ 60 years. Survival time is displayed as time after diagnosis. P-values from
log-rank tests. [Colour figure can be viewed at wileyonlinelibrary.com]
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sAML was associated with a worse outcome [HR 158, 95%
CI (126;190), P < 0001] whereas tAML was not. Gender,
BMI and comorbidity were not associated with inferior OS.
Since we missed information for a minor part of the
cohort (n = 41 for comorbidities and n = 3 for performance
status) we did an imputation of the missing values using pre-
dictive mean matching and a random forest method and the
estimates were not altered significantly (data not shown).
Discussion
In the past decades, knowledge of leukaemia-related factors
as predictive of prognosis has expanded substantially.2
Patient-related factors, such as age and performance status,
are important factors when evaluating eligibility to receive
intensive chemotherapy.18,19 In this large nationwide study,
we have shown that previous and current tobacco usage sig-
nificantly decreases the OS of intensively treated patients
with AML.
To the best of our knowledge, this is the largest nation-
wide study conducted on real-world patients with a complete
follow-up. This set-up allows for a true population-based
design with a limited bias. A major strength of this study is
that information on variables was collected to ensure quality
and is thus free of a hypothesis-limiting information bias.
Information on smoking status was collected at the time of
referral and collected retrospectively for this study, eliminat-
ing recall bias. This study is however not free of bias, as we
were not able to gather information on smoking for approxi-
mately 30% of the included study population. Missing infor-
mation was mainly due to loss of medical records during
transition to electronic patient systems. Some of the retrieved
medical records did however not include information on
smoking history.
To date, a limited number of studies have investigated the
association between smoking status and outcomes in AML.20-22
A retrospective single-centre study by Chelghoum et al. com-
prised of 643 patients with newly diagnosed AML in the time
period of 1984 to 1998 also found inferior OS for smokers.
However, in multivariate analysis, only karyotype and age
remained of prognostic significance for progression-free sur-
vival (PFS) and OS.20 In addition, they demonstrated that a
dose-response relationship with a more intensive or longer
smoking history of smoking is associated with a shorter PFS
and OS and, importantly, smokers were at a higher risk of
severe pulmonary infections during post-chemotherapy
myelosuppression. As in our study, no difference in response
to treatment was observed, measured as CR achievement.
However, the information regarding smoking history was
obtained retrospectively through family members of the
patients, potentially causing recall-bias and potentially con-
founding the results of the study. Similarly, in this period
the different treatment strategies differed, resulting in a more
heterogeneously treated population. Finally, the study was
only able to recruit 75% of patients due to loss of follow-up,
making selection bias likely.
The most recent study by Varadarajan et al. addressed
the prognostic impact of smoking in a single-centre study
comprised of 280 newly diagnosed AML patients between
1990 and 2008.21 All patients received similar intensive
induction therapy, whereas consolidation therapy varied
over time. In line with our study, they found that former
and current smokers had an adverse prognosis. When
adjusting for white blood cell count, gender, age, karyotype
and AML presentation, smoking remained an independent
prognostic factor with a HR of 164 [95% CI (121,221)].
The estimate presented by Varadarajan et al. is comparable
with that of a similar study on smoking habit and outcome
following HSCT,5 which reported a HR for OS of 117
[95% CI (072,191)] and 175 [95% CI (100;306)] for for-
mer and current smoking patients after HSCT, respectively.
However, none of these studies included comorbidity and
WHO performance status as a covariant in the analysis,
which could account for the rather pronounced effect of
smoking on OS, since our data demonstrate ever-smokers
to have significantly more comorbidities compared to
Table III. Multivariate analysis for OS by selected characteristic
(Cox Proportional Hazard modelling, n = 1040).
Characteristics n Hazard ratio (HR) 95% CI P
Smoking
Never 438 100 (reference)
Ever 602 122 104-144 001
Gender
Male 577 100 (reference)
Female 463 089 076-105 0159
Age
< 60 y 556 100 (reference)
≥ 60 y 484 184 156-216 <0001
Comorbidity
0 680 100 (reference)
1 207 113 092–137 0242
≥ 2 112 115 102–167 0034
WHO PS
0 348 100 (reference)
1 501 124 104–148 0016
≥ 2 188 176 141–220 < 0001
BMI
185-249 260 100 (reference)
< 185 13 094 054–164 0821
25-299 210 099 084–118 0934
≥ 30 90 085 067–107 0161
AML presentation
dn-AML 836 100 (reference)
sAML 167 158 126190 < 0001
tAML 37 139 094–206 0099
AML, acute myeloid leukaemia; dn-AML, de novo AML; sAML, sec-
ondary AML; tAML, therapy-related AML; BMI, Body Mass Index;
WHO-PS, World Health Organisation performance score; CI; confi-
dence interval.
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never-smokers. In our study, we were able to adjust for
these potentially confounding factors with a very small
number of missing values. We acknowledge that smoking
status may be related to other impactful covariates not
captured in our study. Intriguingly, alcohol consumption
did not affect survival in any analysis (data not shown).
Another interesting finding in our study is the inferior
median OS observed for men as compared to women for
the total cohort as well as for the non-smoker subset. How-
ever, no difference was observed between ever-smoking
males and females. Also, when comparing median OS in
the smoking strata, female ever-smokers had a significantly
shorter median OS as compared to never-smokers, whereas
this was not observed for men. This could indicate that
females are more susceptible to the chemical compounds of
tobacco. Previous studies have indicated that female smok-
ers have a faster annual decline rate in forced expiratory
volume in one second (FEV1) compared to males.
23,24 How-
ever, whether females are more susceptible to the carcino-
genic compounds of tobacco remains to be further
investigated.
A limitation of our study is the lack of discrimination
between leukaemia-related deaths and all-cause mortality.
Hence, it remains unknown if the increased mortality in the
ever-smoker group is due to leukaemia-related deaths. Previ-
ous studies have shown conflicting reports on the cause of
death. Chelghoum et al. reports an increased prevalence of
invasive pulmonary infections in the smoker group, whereas
Varadarajan et al. did not find an increased risk of infection
among smoking patients.20,21 In general, the effect of smok-
ing habits on invasive pulmonary infections in immunocom-
promised patients seems uncertain.25
Another point of criticism of this study is the failure of
quantifying the intensity, duration and cessation of smok-
ing (e.g., expressed as pack-years). This was largely due to
inconsistent information in medical records. Data on
smoking habits were retracted from the medical record
taken at the very first admission to the haematology
department by the physician taking care of the patient.
Since the medical records are based on patient-reporting,
information bias is possible. Patients have a tendency to
underreport smoking habits and smokers may have been
categorised as non-smokers – we may thereby inadvertently
have underestimated the effects of smoking. We also
pooled former and current smokers into one stratum, and
were therefore not able to scrutinise the effect of former
smoking versus current smoking. Pooling former and cur-
rent smokers in an ‘ever-smokers’ group may thus underes-
timate the actual prognostic effects of active tobacco-
smoking. Finally, data on laboratory values, cytogenetics
and on mutational status were not available. Our study is
not able to point out the exact mechanism or effect of
tobacco-smoking on outcome parameters. Previous studies
have investigated the association between tobacco-smoking
and cytogenetic findings in AML, summarised in Ref.[26].
Smoking has been associated with abnormalities of chro-
mosome 8 [especially trisomy 8 and t(8,21)] and chromo-
some 7 [del(7) or del(7q)]. However, the two previous
studies investigating the prognostic association of smoking
did not find any differences in the cytogenetic risk category
between smoking and non-smoking strata [19,20]. A recent
presentation by Alfayez et al. also found smoking to be
associated with inferior OS in univariate analysis, but not
in multivariate.27 They also found smoking to be associated
with poor European Leukemia Net (ELN) risk, complex
karyotype and GATA2 mutation when controlling for age.
This unpublished work indicates the possibility that the
inferior OS associated with smoking could be explained by
altered biology, rather than with the comorbidity associated
with smoking.27 Since the abovementioned studies, includ-
ing our own, are correlational of nature, they do not imply
a causal relationship between smoking status and inferior
OS in AML patients. To shed light on this matter, further
investigations are needed to elucidate whether smoking
alters the underling biology, including the mutational pro-
file of AML.
In conclusion, our present study confirms smoking status
as an important patient-related prognostic factor for out-
come in a Danish cohort of AML patients, intensively treated
between 2000 and 2012. This association was independent of
gender, performance status, comorbidities, age, AML-presen-
tation and BMI. Due to the observational and hypothesis-
generating character of this study, it remains uncertain
whether tobacco-smoking affects OS in patients with AML
through leukaemia-related (e.g., somatic mutations) or
patient-related (e.g., pulmonary morbidity) factors. We sug-
gest that future studies on this subject should aim to include
socio-economic and leukaemia-related prognostic factors to
study the exact mechanism of inferior survival in previous
and current smokers with AML.
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